Dec 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arcutis Biotherapeutics, Artiva Biotherapeutics and Nuvalent on Monday.
HIGHLIGHTS
* Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating |
* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating |
* Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110 |
Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order
* Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating |
* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating |
* BigBear.ai Holdings Inc BBAI.N: H.C. Wainwright raises PT to $7 from $3 |
* Boston Scientific Corp BSX.N: BTIG raises target price to $101 from $97 |
* Emergent Biosolutions EBS.N: H.C. Wainwright initiates coverage with buy rating; PT $15 |
* Exelixis Inc EXEL.O: RBC raises target price to $38 from $34 |
* Insulet Corp PODD.O: BTIG raises target price to $300 from $270 |
* Metavia Inc MTVA.O: H.C. Wainwright initiates coverage with buy rating; PT $12 |
* Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110 |
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。